BioSpace News Archive

Results from a Phase 3 clinical study for treatment of agitation in patients with Alzheimer’s dementia showed that patients treated with brexpiprazole had a statistically significantly greater reduction in agitation compared to placebo Agitation is a very prevalent clinical manifestation in Alzheimer’s dementia and one of the most complex and stressful aspects of care in patients affected by the disease.

Volpara Health Technologies announced a new research and development agreement with Microsoft to accelerate the creation of a solution that detects and quantifies breast arterial calcifications.

CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, began a new era in plasma donations, collecting its first plasma donations using leading-edge plasma collection technology that is expected to significantly reduce average collection time – by approximately one-third – and improve the donor experience.

Xoran Technologies® announces that last month it received FDA 510 clearance for TRON® — a truly mobile, full-body fluoroscopy, computed tomography X-ray system.

Chinook Therapeutics, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 24,700 shares of common stock with a grant date of July 29, 2022 for one new employee.

Aligos Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, reported recent business progress and financial results for the second quarter June 30, 2022.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, reported second quarter 2022 financial results and recent corporate highlights.

Lyell Immunopharma, Inc., a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, provided business highlights and reported financial results for the second quarter of 2022.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, reported its financial results for the quarter ended June 30, 2022 and provided a corporate update.

Eledon Pharmaceuticals, Inc. announced that it plans to release financial results for the second quarter ended June 30, 2022 on Thursday, August 11, after the close of trading.